Best Artificial Tears for Dry Eye: The One My Patient Eventually Doesn’t Need

Which artificial tear do I recommend for dry eye? My answer is pretty consistent, and it starts with why the patient needs drops at all.

By Christopher Wolfe, OD, FAAO, Dipl. ABO
Co-founder, Peeq Pro

I get asked fairly frequently which artificial tear I recommend for patients with dry eye disease.

It's a reasonable question, and I have a fairly consistent answer. But before I get into which drops I recommend, I think it's important to understand how I approach treating ocular surface disease in my practice.

Why Artificial Tears Aren't My First Dry Eye Treatment

We don't put artificial tears in our dry eye treatment box as an initial treatment because our goal is to eliminate the need for them.

That doesn't mean I don't recommend artificial tears; I still prescribe them occasionally. But I generally view them as a way to manage symptoms while we address the underlying reasons the patient is experiencing those symptoms.

When a patient comes into my office using artificial tears four, five, or six times a day, my goal isn't to find them a better drop that they can use six times a day. My goal is to understand why they need the drops in the first place.

And if we can address those underlying issues, we can typically get them to the point where they only need artificial tears occasionally, or ideally, not at all.

What Are We Actually Treating? Evaporative vs. Aqueous-Deficient Dry Eye

Most of the patients I see with ocular surface disease don't fit neatly into one category.

Historically, we've divided dry eye into aqueous-deficient and evaporative disease. That classification is helpful, but in clinical practice, there is considerable overlap.

Patients with meibomian gland dysfunction frequently have tear-film instability, inflammation, and secondary changes to the ocular surface. Patients with aqueous deficiency can also have significant evaporative components.

In my experience, the majority of patients I treat have at least some evaporative component to their disease, and frequently it is the predominant mechanism.

That influences how I select artificial tears.

If I am going to recommend a product to help a patient manage symptoms while we work on the underlying disease, I generally want something that provides hydration while also supporting the lipid layer and reducing evaporation.

Simply adding more aqueous volume to an unstable tear film may provide temporary relief, but it doesn't necessarily address why that tear film is unstable.

This is especially apparent in patients who tell me their vision becomes blurry later in the day, clears when they blink, or becomes uncomfortable during prolonged computer use.

These patients may have adequate aqueous tear production, but the tears aren't remaining stable on the ocular surface.

For those patients, a conventional aqueous lubricant is not the most logical first choice.

So Which Artificial Tear Do I Recommend for Dry Eye?

When I don't have a compelling reason to select a more specialized formulation, I typically recommend a preservative-free artificial tear that addresses both hydration and evaporation.

There are several products that fit that description.

Systane Complete PF, Refresh Optive Mega-3, OPTASE MGD Advanced, Blink Triple Care PF, and Retaine MGD Advanced are examples of products designed to support the tear film through lipid supplementation and, depending on the formulation, additional lubricating or hydrating mechanisms.

I don't think there is one artificial tear that is universally superior for every patient. I am more interested in the mechanism of action than the brand on the bottle.

For example, lipid-containing formulations can supplement the tear-film lipid layer, while ingredients such as hyaluronic acid, glycerin, and carboxymethylcellulose can help retain moisture and support lubrication.

Some formulations combine several of these mechanisms.

For a patient with mixed ocular surface disease, particularly when evaporation is prominent, that combination makes sense to me.

I also tend to favor preservative-free formulations, especially when patients need frequent lubrication or have an already compromised ocular surface.

The lipid-plus-hydration drops Dr. Wolfe names

All preservative-free. Pick by mechanism, not by the brand on the bottle.

Systane Complete PF Lipid nanoemulsion with propylene glycol and HP-Guar View drop Refresh Optive Mega-3 Castor oil lipid emulsion with hydrating lubricants View drop OPTASE MGD Advanced Glycerin with a lipid microemulsion and trehalose View drop Retaine MGD Mineral oil lipid nanoemulsion View drop

Blink Triple Care PF fits the same description. Stocking these for your patients? Get wholesale pricing.

When I Choose Something Different

But there are certainly exceptions.

If I have a patient with significant aqueous deficiency, I would often utilize punctal occlusion or filling with Lacrifill gel, but if needed, I will prioritize a formulation with hyaluronic acid or greater viscosity. If a patient has nocturnal exposure, a nighttime gel or ointment may be more appropriate. And if a patient wears contact lenses, I need to consider the compatibility of the product with their lenses.

The diagnosis should drive the product selection, rather than the product determining how we treat the diagnosis.

Artificial Tears Are a Bridge, Not the Destination

The reason I don't build my dry eye treatment strategy around artificial tears is that they generally don't correct the underlying mechanisms responsible for chronic ocular surface disease.

If a patient has obstructive meibomian gland dysfunction, an artificial tear isn't going to restore normal meibomian gland function.

If they have significant ocular surface inflammation, lubrication alone may not adequately control that inflammation.

If incomplete blinking, environmental exposure, or eyelid abnormalities are contributing to the problem, those factors still need to be addressed.

In my practice, that may involve treating meibomian gland dysfunction with thermal therapies, IPL, or other appropriate interventions. It may involve prescription anti-inflammatory therapy, addressing eyelid disease, modifying environmental factors, or managing aqueous deficiency when present.

Artificial tears can help patients remain comfortable while those interventions begin to improve the ocular surface.

And for some patients, continued supplemental lubrication will remain an appropriate part of long-term management.

But I don't want patients to confuse temporary symptom relief with successful treatment of their disease.

If a patient tells me that their artificial tears work great for about ten minutes, that tells me something clinically useful.

It tells me we probably haven't adequately addressed the mechanism responsible for their symptoms.

The answer may not be another artificial tear.

What Should We Be Measuring in Dry Eye Management?

I think one of the challenges in dry eye management is that it's relatively easy to measure how many products a patient is using, but that doesn't necessarily tell us how well we're managing their disease.

A patient may be very compliant with artificial tears and still have significant ocular surface disease.

I would much rather evaluate whether we've improved tear-film stability, reduced ocular surface staining, addressed meibomian gland dysfunction, and improved the patient's symptoms and visual function.

And I want to know whether the patient is becoming less dependent on supplemental lubrication.

If someone comes into my office using artificial tears six times a day and, after treatment, is comfortable using them once or twice a week, I consider that a meaningful clinical improvement, assuming their objective findings support it.

That doesn't mean eliminating artificial tears is the appropriate endpoint for everyone. Some patients have chronic conditions that require continued lubrication.

But reducing unnecessary dependence on symptomatic therapy is a reasonable goal when we can improve the underlying disease.

The Recommendation I Give Most Often

So when someone asks me which artificial tear I recommend most frequently, my answer is relatively straightforward.

For the typical patient with mixed ocular surface disease, particularly when evaporative disease predominates, I generally recommend a preservative-free formulation that combines hydration with lipid-layer support.

I want a product that can help stabilize the tear film and improve comfort while we're addressing the underlying disease.

I don't need patients trying five different artificial tears to find the one that makes them feel better for another twenty minutes.

I need to understand what's happening on their ocular surface and develop a treatment plan that improves its function.

Artificial tears absolutely have a role in that process. They can provide meaningful relief, protect the ocular surface, and help patients remain comfortable during treatment.

But when I think about the long-term success of dry eye management, I don't measure it by how many bottles of artificial tears a patient purchases.

I measure it by how well their ocular surface functions without having to depend on them.

And that's why, when I recommend an artificial tear, I'm usually hoping it's something my patient eventually won't need nearly as often.

Get your free Eye Drop Guide

Dr. Wolfe's mechanism-first approach, turned into a quick reference for your whole team: which drop, for which patient. Brand-agnostic by design. Fill out the short form and it lands in your inbox in minutes.

Bonus: a one-page artificial tear quick reference from Dr. Wolfe, ready to print for the tech station.

Download the PDF

Curious how you recommend drops? Take the one-minute drop personality quiz.

Frequently Asked Questions About Artificial Tears

Christopher Wolfe, OD, FAAO, Dipl. ABO

Dr. Wolfe is a co-founder of Peeq Pro and a practicing optometrist with deep expertise in specialty contact lenses and ocular surface disease. He builds Peeq Pro's clinical resources with co-founder Dr. Cheryl Chapman.

Connect with Dr. Wolfe on LinkedIn

This article is clinical education for eye care professionals and is not medical advice for individual patients. Product selection should be individualized by the treating clinician and follow current product labeling. Product names are trademarks of their respective owners; mentions are examples, not endorsements of one brand over another.